M
Marek Ancukiewicz
Researcher at Harvard University
Publications - 143
Citations - 20032
Marek Ancukiewicz is an academic researcher from Harvard University. The author has contributed to research in topics: Radiation therapy & Bevacizumab. The author has an hindex of 56, co-authored 142 publications receiving 18390 citations. Previous affiliations of Marek Ancukiewicz include University of Colorado Denver & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer
Christopher G. Willett,Dan G. Duda,Marek Ancukiewicz,Mira Shah,Brian G. Czito,Rex C. Bentley,Martin Poleski,Hiroshi Fujita,Gregory Y. Lauwers,M. Carroll,Douglas S. Tyler,Christopher R. Mantyh,Paul C. Shellito,Daniel C. Chung,Jeffrey W. Clark,Rakesh K. Jain +15 more
TL;DR: Overall survival, disease-free survival, and local control showed favorable trends in patients treated with bevacizumab with chemoradiation followed by surgery, and promising long-term efficacy and safety profiles in locally advanced rectal cancer patients are shown.
Journal ArticleDOI
A simple clinical predictive index for objective estimates of mortality in acute lung injury.
Colin R. Cooke,Chirag V. Shah,Robert Gallop,Scarlett L. Bellamy,Marek Ancukiewicz,Mark D. Eisner,Paul N. Lanken,A. Russell Localio,Jason D. Christie +8 more
TL;DR: Mortality in patients with ALI can be predicted using an index of four readily available clinical variables with good calibration, and there was an excellent agreement between predicted and observed mortality in the validation cohort.
Journal ArticleDOI
Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?
TL;DR: A set of 35 plasma biomarkers in NSCLC patients at four time-points after antiangiogenic therapy alone with the VEGF receptor 2 tyrosine kinase inhibitor (TKI) vandetanib, chemotherapy alone, or a combination of the two were explored.
Journal ArticleDOI
Assessing uncertainty in cost-effectiveness analyses : application to a complex decision model
Giovanni Parmigiani,Greg Samsa,Marek Ancukiewicz,Joseph Lipscomb,Vic Hasselblad,David B. Matchar +5 more
TL;DR: A framework for quantifying uncertainty about costs, effectiveness measures, and mar ginal cost-effectiveness ratios in complex decision models is presented and two alternative approaches, one based on Bayesian inference and the other on resampling are discussed.
Journal ArticleDOI
Association of physical examination with pulmonary artery catheter parameters in acute lung injury
Colin K. Grissom,Alan H. Morris,Paul N. Lanken,Marek Ancukiewicz,James F. Orme,David A. Schoenfeld,B. Taylor Thompson +6 more
TL;DR: It is hypothesized that physical examination findings of ineffective circulation and objective parameters obtained without a PAC are associated with a low CI and SvO2 in patients with acute lung injury (ALI) and acute respiratory distress syndrome.